Table 3.
Model 1 | Model 1 + TC | Model 1 + LDL-C | Model 1 + TC and LDL-C# | |
---|---|---|---|---|
Per 1SD (17.6ng/ml) | 1.43 (1.10 – 1.85)b | 1.42 (1.09 – 1.85)a | 1.46 (1.12 – 1.89)b | 1.42 (1.09 – 1.85)a |
Sortilin quartile | ||||
Quartile 1 | 1.00 | 1.00 | 1.00 | 1.00 |
Quartile 2 | 1.02 (0.54 – 1.95) | 1.01 (0.53 – 1.93) | 1.08 (0.56 – 2.07) | 1.08 (0.56 – 2.07) |
Quartile 3 | 1.40 (0.72 – 2.70) | 1.39 (0.72 – 2.68) | 1.42 (0.74 – 2.75) | 1.41 (0.73 – 2.74) |
Quartile 4 | 2.19 (1.12 – 4.30)b | 2.14 (1.08 – 4.24)a | 2.29 (1.16 – 4.53)b | 2.14 (1.08 – 4.26)a |
Quartile 1–3 | 1.00 | 1.00 | 1.00 | 1.00 |
Quartile 4 | 1.94 (1.12 – 3.36)a | 1.91 (1.09 – 3.32)a | 1.99 (1.14 – 3.45)a | 1.86 (1.06 – 3.25)a |
p<0.05;
p<0.01;
the interaction was not significant.
Quartile 1, <60 ng/mL; Quartile 2, >60 – 72 ng/mL; Quartile 3, >72 – 85 ng/mL; Quartile 4, >85 ng/ml.
TC; total cholesterol, LDL-C; low density lipoprotein cholesterol.
Model 1, adjusted for age, fat mass, body height, current smoking, self-reported coronary heart disease, blood pressure, self-reported pharmacologically treated diabetes mellitus, calcium intake, vitamin D and calcium supplements, vitamin K-antagonists, calcium channel blockers, phosphorus, calcium and interaction between calcium and phosphorus.